Overview

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous treatment with Bacille Calmette Guérin (BCG).
Phase:
Phase 2
Details
Lead Sponsor:
Viventia Bio